We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Exploring Analyst Estimates for Cardinal (CAH) Q1 Earnings, Beyond Revenue and EPS
Read MoreHide Full Article
Analysts on Wall Street project that Cardinal Health (CAH - Free Report) will announce quarterly earnings of $1.64 per share in its forthcoming report, representing a decline of 5.2% year over year. Revenues are projected to reach $51.26 billion, declining 6.4% from the same quarter last year.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Given this perspective, it's time to examine the average forecasts of specific Cardinal metrics that are routinely monitored and predicted by Wall Street analysts.
The combined assessment of analysts suggests that 'Revenue- Pharmaceutical and Specialty Solutions' will likely reach $47.22 billion. The estimate indicates a year-over-year change of -6.8%.
The collective assessment of analysts points to an estimated 'Revenue- Medical Products and Distribution' of $3.13 billion. The estimate points to a change of +1.9% from the year-ago quarter.
Based on the collective assessment of analysts, 'Segment profit- Pharmaceutical and Specialty Solutions' should arrive at $459.78 million. The estimate is in contrast to the year-ago figure of $507 million.
According to the collective judgment of analysts, 'Segment profit- Global Medical Products and Distribution' should come in at $27.06 million. The estimate is in contrast to the year-ago figure of $71 million.
Over the past month, shares of Cardinal have returned +0.3% versus the Zacks S&P 500 composite's +1.7% change. Currently, CAH carries a Zacks Rank #2 (Buy), suggesting that it may outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Exploring Analyst Estimates for Cardinal (CAH) Q1 Earnings, Beyond Revenue and EPS
Analysts on Wall Street project that Cardinal Health (CAH - Free Report) will announce quarterly earnings of $1.64 per share in its forthcoming report, representing a decline of 5.2% year over year. Revenues are projected to reach $51.26 billion, declining 6.4% from the same quarter last year.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective.
Given this perspective, it's time to examine the average forecasts of specific Cardinal metrics that are routinely monitored and predicted by Wall Street analysts.
The combined assessment of analysts suggests that 'Revenue- Pharmaceutical and Specialty Solutions' will likely reach $47.22 billion. The estimate indicates a year-over-year change of -6.8%.
The collective assessment of analysts points to an estimated 'Revenue- Medical Products and Distribution' of $3.13 billion. The estimate points to a change of +1.9% from the year-ago quarter.
Based on the collective assessment of analysts, 'Segment profit- Pharmaceutical and Specialty Solutions' should arrive at $459.78 million. The estimate is in contrast to the year-ago figure of $507 million.
According to the collective judgment of analysts, 'Segment profit- Global Medical Products and Distribution' should come in at $27.06 million. The estimate is in contrast to the year-ago figure of $71 million.
View all Key Company Metrics for Cardinal here>>>
Over the past month, shares of Cardinal have returned +0.3% versus the Zacks S&P 500 composite's +1.7% change. Currently, CAH carries a Zacks Rank #2 (Buy), suggesting that it may outperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>